Posted by Michael Wonder on 23 Apr 2020
Revised PBS listings for hydroxychloroquine for the treatment of auto-immune disorders and malaria from 1 May 2020
23 April 2020 - Commencing 1 May 2020, the Pharmaceutical Benefits Scheme listings for hydroxychloroquine will change.
The current general unrestricted benefits listing of hydroxychloroquine on the Pharmaceutical Benefits Scheme (PBS) is split into separate initial and continuing treatment listings for the TGA approved indications of malaria or autoimmune disorders.
Both initial and continuing PBS listings will be Authority Required (STREAMLINED). Under the initial PBS listing, initial therapy must be authorised by a medical practitioner of any of the specialities defined in the clinical criteria.
